ArticleDiabetes, metabolic syndrome and obesity : targets and therapy2025
Association Between Thyroid Hormone Sensitivity and Non-Alcoholic Fatty Liver Disease in Individuals with Normal Thyroid Function.
Article in Diabetes, metabolic syndrome and obesity : targets and therapy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Metabolic and hepatic differences among biochemically euthyroid individuals with distinct thyroid hormone sources: a comparative study.BMC endocrine disorders · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Nonalcoholic fatty liver disease (NAFLD) is a globally prevalent metabolic disorder that has attracted increasing clinical and public health attention. Although several studies have suggested a potential link between thyroid hormone levels and the risk of NAFLD, existing epidemiological evidence remains limited and inconsistent. Therefore, this study aims to investigate the association between thyroid hormone sensitivity and NAFLD in individuals with normal thyroid function. Furthermore, we sought to explore whether this association differs according to the presence or absence of metabolic comorbidities, particularly type 2 diabetes mellitus (T2DM) and non-diabetic (non-DM) status. Methods: We included 460 adults with normal thyroid function, comprising 229 patients with T2DM and 231 without diabetes. Steatosis was assessed using liver ultrasonography. Results: Both the thyroid feedback quantile index based on free thyroxine (TFQI-FT4) and that based on free triiodothyronine (TFQI-FT3) were positively associated with the presence of NAFLD (Q4 vs Q1, Model 3: TFQI-FT4, OR = 3.290, 95% CI: 1.390-7.787, p = 0.007; TFQI-FT3, OR = 2.344, 95% CI: 1.010-5.439, p = 0.047). Among individuals with type 2 diabetes mellitus (T2DM), a higher FT3/FT4 ratio was associated with a lower risk of NAFLD (Q3 vs Q1, Model 2: OR = 0.221, 95% CI: 0.053-0.921, p = 0.038), although the comparison between Q4 and Q1 did not reach statistical significance (OR = 0.402, 95% CI: 0.100-1.614, p = 0.199). In contrast, among non-diabetic individuals, a higher FT3/FT4 ratio was positively associated with NAFLD (Q4 vs Q1, Model 2: OR = 3.390, 95% CI: 1.003-11.463, p = 0.049). Conclusion: Thyroid hormone sensitivity is associated with the development of NAFLD development in individuals with normal thyroid function and may be influenced by the presence of T2DM.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.